Managed Healthcare Executive November 4, 2025
Key Takeaways
- Bipartisan legislation aims to allow Medicare coverage for FDA-approved obesity medications and specialist visits, potentially benefiting patients and the healthcare system.
- Expanding access to GLP-1 medications could save Medicare up to $245 billion over 10 years by reducing demand for other services.
- The high cost of GLP-1 medications and insurance industry resistance are significant challenges to expanding coverage.
- Previous legislative efforts have failed, but there is optimism for future success in expanding Medicare coverage for obesity treatments.
It may take legislation for it to happen, but the Trump administration is reportedly going to test coverage on an experimental basis.
Although the Trump administration shot down a Biden-era proposal that would have required Medicare to cover obesity...
Today's Sponsors
Today's Sponsor